Management Articles

Bariatric surgery is an efficient method ? to achieve significant weight loss for NASH/NAFLD, learn more from our management articles.

Eight recommendations to improve NAFLD care models

Authors: Lazarus JV, Anstee QM, Hagstrom H, et al.
Published in Nat Rev Gastroenterol Hepatol 2021
Little attention has been given to the design and implementation of efficient and effective models of care for patients with NAFLD. In many health-care settings, no formal pathways exist, or are often not standardised according to good practices...
Read MoreEight recommendations to improve NAFLD care models

Pharmacotherapy in NAFLD/NASH

Authors: Attia SL, Softic S, Mouzaki M.
Published in Clin Transl Sci 2021
This review by SL Attia et al. (University of Kentucky College of Medicine, USA) summarises emerging pharmacotherapies for the treatment of adult and paediatric NAFLD. Investigated pharmacotherapies include lanifibranor (IVA337), an indole sulfonamide PPAR agonist that activates....
Read MorePharmacotherapy in NAFLD/NASH

European NAFLD guidelines: limitations when applied to T2D patients

Authors: Besutti G, Bonilauri L, Manicardi E, et al.
Published in Diabetes Res Clin Pract 2021
G. Besutti et al. aimed to evaluate the feasibility and efficiency of a guidelines-compliant NAFLD assessment algorithm in patients with newly diagnosed type 2 diabetes. Consecutive patients newly diagnosed with T2D without coexisting liver disease or excessive alcohol consumption were enrolled. They were stratified...
Read MoreEuropean NAFLD guidelines: limitations when applied to T2D patients

NAFLD/NASH-related liver fibrosis: mechanisms, treatment, and prevention

Authors: Tacke F, Weiskirchen R.
Published in Ann Transl Med 2021
NAFLD or NASH are nowadays the leading causes of hepatic fibrosis worldwide. In their review, F. Tacke (Charité University Medicine, Berlin, Germany) and R. Weiskirchen (RWTH University Hospital, Aachen, Germany) discuss recent advances in antifibrotic prevention and therapy....
Read MoreNAFLD/NASH-related liver fibrosis: mechanisms, treatment, and prevention

Immunotherapy-treated HCC: NASH limits anti-tumour surveillance

Authors: Pfister D, Nunez NG, Pinyol R, et al
Published in Nature 2021
Immunotherapy has been approved for treating hepatocellular carcinoma (HCC), but biomarker-based stratification of patients for optimal response to therapy is an unmet need. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) did not lead...
Read MoreImmunotherapy-treated HCC: NASH limits anti-tumour surveillance

Fibrosis in NASH: targeted therapies

Authors: Huisman TM, Dieterich DT, Friedman SL
Published in J Exp Pharmacol 2021
Progress in uncovering pathogenic determinants of fibrosis in NASH include metabolic dysregulation in hepatocytes that induce inflammation and cytokine secretion leading to cell injury and apoptosis, among others.This review by T. M. Huisman et al. (Division of Liver Diseases, Icahn School of Medicine at Mount Sinai...
Read MoreFibrosis in NASH: targeted therapies

Management of NAFLD: a review

Authors: Petroni ML, Brodosi L, Bugianesi E, et al.
Published in BMJ 2021
As explained in the review by M. L. Petroni et al. (“Alma Mater” University, Bologna, Italy), several drugs are under investigation according to the agreed targets of reduced NASH activity without worsening of fibrosis or improving fibrosis without worsening of NASH. Anti-inflammatory, anti-fibrotic agents and metabolism modulators...
Read MoreManagement of NAFLD: a review

Comparative analysis of different guidelines

Authors: LAndo Y, Jou JH
Published in Clin Liver Dis (Hoboken) 2021
In their review, Y. Ando and J. H. Jou (Oregon Health & Science University Hospital, Portland, Oregon, USA) summaries updated guideline and guidance recommendations for the management of adult NAFLD. They highlight key difference between US, Asian, and European recommendations; and provide key updates...
Read MoreComparative analysis of different guidelines

Is Europe ready to meet the challenge of fatty liver disease?

Authors: Lazarus JV, Palayew A, Carrieri P, et al
Published in JHEP Rep 2021
NAFLD is closely associated with obesity, metabolic syndrome, and diabetes. NAFLD can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to allow for effective public health measures. NAFLD preparedness means having adequate policies and civil society...
Read MoreIs Europe ready to meet the challenge of fatty liver disease?

NAFLD: a year in review

Authors: Abdelmalek MF.
Published in Nat Rev Gastroenterol Hepatol 2021
he field of NAFLD and its progressive form, NASH, has, despite the challenges of the COVID-19 pandemic, continued to rapidly evolve in 2020. There have been substantial advances in NAFLD mechanisms, diagnostics, and treatment. Key developments include the identification of a multiparametric cellular and tissue signature to define disease progression...
Read MoreNAFLD: a year in review

Current management of NASH

Authors: Muthiah MD, Sanyal AJ.
Published in Liver Int 2020
NASH is the most common cause of liver disease in Western populations, and its prevalence is increasing rapidly. It is a multifactorial and multisystem disease that can affect multiple organs such as the kidneys, heart and blood vessels, and is closely associated with the components of the metabolic syndrome...
Read MoreCurrent management of NASH

Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.

Authors: Wang ST, Zheng J, Peng HW, et al.
Published in BMC Gastroenterol 2020
Nowadays, dramatic changes in the lifestyle and diet of the global population are causing the prevalence of NAFLD increasing rapidly, in parallel with that of obesity and diabetes. Previous studies found an inverse relationship between physical activity and the risk of NAFLD. However, clinical trials...
Read MorePhysical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES